The advent of high-throughput and unbiased proteogenomic screens promises to rapidly advance our understanding of the molecular mechanisms underpinning pathogenesis of lymphoid malignancies. The wealth of data generated from these studies requires methods to rapidly confirm and extend findings into cell line models and primary patient samples. The proximity ligation assay (PLA) is a method that can visualize protein–protein interactions in situ. PLA can capture transient interactions and characterize constituents of stable biomolecular condensates, both of which pose technical difficulties for traditional biochemical and fluorescence imaging techniques.